
Dr DeAngelo on the Current Treatment Paradigm for Myelofibrosis
Daniel DeAngelo MD, PhD, discusses current treatment strategies for patients with myelofibrosis, highlighting ongoing and recently presented studies
Daniel DeAngelo MD, PhD, professor, medicine, Harvard Medical School; physician, chief, Division of Leukemia, Dana-Farber Cancer Institute,
The current standard of care for managing myelofibrosis is tailored based on risk assessment, DeAngelo begins. For patients identified as high risk or those exhibiting symptomatic disease, including symptomatic splenomegaly, the initiation of JAK inhibition is recommended, he explains. DeAngelo states that ruxolitinib (Jakafi) has historically been the primary treatment option for these patients, but 3 additional JAK inhibitors have recently gained FDA approval for patients with myelofibrosis. One of these, fedratinib (Inrebic), shares similarities with ruxolitinib; however, both medications are known to cause anemia as a common adverse effect, he reports.
Recent studies have contributed significantly to the development of ruxolitinib-containing regimens for myelofibrosis, according to DeAngelo. Two notable combination trials were recently presented, DeAngelo continues.
Similarly,

